Drug Delivery News and Research

RSS

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.

Einstein researchers to develop drug-impregnated intravaginal ring for HIV prevention in women

Researchers at Albert Einstein College of Medicine of Yeshiva University have been awarded a $12 million grant from the National Institutes of Health (NIH) to develop a drug-impregnated intravaginal ring to prevent HIV infection in women.

11 Mar 2013

Online mobile phone app for users of CME Medical’s T34 Ambulatory Syringe Pump

CME Medical, the UK’s fastest growing specialist infusion company, has launched a new online mobile phone app for users of the company’s T34TM Ambulatory Syringe Pump . The app demonstrates the company’s commitment to developing accessible education programmes for all of its customers. It incorporates information which is also available in printed Quick User Guides and helps people through the process of using the pump. The app can be used on any device with an internet connection.

6 Mar 2013

UPV/EHU team uses lipid nanoparticles to develop new formulations for drug delivery

At the Faculty of Pharmacy of the Basque Public University (UPV/EHU) the Pharmacokinetics, Nanotechnology and Gene Therapy research team is using nanotechnology to develop new formulations that can be applied to drugs and gene therapy.

1 Mar 2013

New implantable sensor holds promise for advancing personalized medicine

Rebecca Wachs has invented a new implantable sensor with the ability to wirelessly transmit data from the site of a knee replacement, spinal fusion, or other orthopedic surgery.

28 Feb 2013

FDA accepts Antares Pharma's New Drug Application for OTREXUP

Antares Pharma, Inc. today announced that the New Drug Application for OTREXUP, a potential new product for the subcutaneous delivery of methotrexate using Medi-Jet technology, has been accepted by the U.S. Food and Drug Administration indicating that the application is sufficiently complete to permit a substantive review.

27 Feb 2013

Ampio Pharmaceuticals starts Optina clinical trial

Ampio Pharmaceuticals, Inc. announced oral dosing of the first patient in a 505(b)(2) clinical trial of the investigational drug Optina in diabetic macular edema.

27 Feb 2013

Pharmaceutical research centre led by the University of Limerick to receive investment from Science Foundation Ireland

A research centre led by the University of Limerick dedicated to supporting the pharmaceutical industry in Ireland will benefit from today’s announcement of €300 million investment by Science Foundation Ireland. The Irish pharmaceutical industry supports over 60,000 Irish jobs and exports over €50 billion annually.

26 Feb 2013

New materials mimic mussel adhesive proteins for three medical applications

When it comes to sticking power under wet conditions, marine mussels are hard to beat. They can adhere to virtually all inorganic and organic surfaces, sustaining their tenacious bonds in saltwater, including turbulent tidal environments.

18 Feb 2013

Researchers develop nano-machines that recreate principal activities of proteins

Physicists of the University of Vienna together with researchers from the University of Natural Resources and Life Sciences Vienna developed nano-machines which recreate principal activities of proteins.

16 Feb 2013

Oramed to submit new oral insulin IND with FDA

Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today that it has been in communication with the U.S. Food and Drug Administration (FDA) regarding its Investigational New Drug (IND) application for oral insulin.

15 Feb 2013

SPI Pharma launches Actimask Ibuprofen 92S

SPI Pharma, Inc., a global leader in providing pharmaceutical ingredients and technologies for patient-friendly dosage forms, announces the launch of Actimask Ibuprofen 92S, a taste-masked Ibuprofen.

15 Feb 2013

Cambrex, Dow partner to manufacture HPMCAS for drug solubility enhancement

Cambrex and The Dow Chemical Company have executed an agreement for Cambrex to contract manufacture Dow Hydroxypropyl Methylcellulose Acetate Succinate (HPMCAS) for Drug Solubility Enhancement.

15 Feb 2013

New drug delivery system can reduce size of ovarian tumors by as much as 83%

By loading fragile RNA into silicon nanoparticles, researchers from The Methodist Hospital and two other institutions found a new drug delivery system can reduce the size of ovarian tumors by as much as 83 percent -- and stop tumor growth in chemotherapy-resistant ovarian cancer tissue.

13 Feb 2013

Unilife revenues decrease to $0.7 million for three months ended December 31, 2012

Unilife Corporation, a developer and supplier of injectable drug delivery systems, today announced its financial results for the quarter ended December 31, 2012, (the second quarter of Fiscal Year 2013).

12 Feb 2013

Drug-carrying nanoparticles have another hurdle to overcome - escaping the bloodstream

Many medically minded researchers are in hot pursuit of designs that will allow drug-carrying nanoparticles to navigate tissues and the interiors of cells, but University of Michigan engineers have discovered that these particles have another hurdle to overcome: escaping the bloodstream.

7 Feb 2013

BD first quarter revenues increase 3.7% to $1.90 billion

BD, a leading global medical technology company, today reported quarterly revenues of $1.90 billion for the first fiscal quarter ended December 31, 2012, representing an increase of 3.7 percent from the prior-year period, or 5.2 percent on a foreign currency-neutral basis.

From BD (Becton, Dickinson and Company) 5 Feb 2013

Cloaked nanoparticles escape immune system surveillance to reach desired target

By cloaking nanoparticles in the membranes of white blood cells, scientists at The Methodist Hospital Research Institute may have found a way to prevent the body from recognizing and destroying them before they deliver their drug payloads. The group describes its "LeukoLike Vectors", or LLVs, in the January issue of Nature Nanotechnology.

4 Feb 2013

Celsion's ThermoDox does not meet primary endpoint in Phase III HCC study

Celsion Corporation, a leading oncology drug development company, today announced that ThermoDox in combination with radiofrequency ablation (RFA) did not meet the primary endpoint of the Phase III HEAT Study in patients with hepatocellular carcinoma (HCC), also known as primary liver cancer.

31 Jan 2013

Organizing the Nano World Cancer Day: A European multi-sites event in Paris, Braga and Berlin

In the framework of the World Cancer Day, the European Technology Platform of Nanomedicine (ETPN) and its partners will organize a European event on February the 1st on "How nanomedicine contributes to better cancer diagnostic and therapy". Similar and simultaneous events will be organized in France and Portugal, highlighting the importance of nanomedicine research for cancer on the European level.

31 Jan 2013

Enzymes may have new role as intelligent micro and nanomotors

Enzymes, workhorse molecules of life that underpin almost every biological process, may have a new role as "intelligent" micro- and nanomotors with applications in medicine, engineering and other fields.

31 Jan 2013